Pfizer stock licenses CAR-T programs in 2.6 billion US dollar deal
Published on 11/19/2026 at 14:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer expands its autoimmune pipeline
- Pfizer secured exclusive rights outside Greater China to three pre-IND in vivo CAR-T programs from Starna Therapeutics.
- The agreement adds applications in inflammation, immunology and oncology to Pfizer's development strategy.
- Pfizer will lead development outside Greater China and retain exclusive commercialization control in those markets.
Pfizer said on Wednesday, November 18, that it had entered an exclusive licensing agreement with Starna Therapeutics covering three pre-IND in vivo CAR-T programs focused on autoimmune diseases. The announcement was made in a Pfizer press release.
Pfizer receives exclusive rights outside Greater China to develop, manufacture and commercialize the three programs. The agreement also gives Pfizer rights to use Starna's in vivo CAR-T technology in inflammation and immunology, as well as oncology. Pfizer has options to license additional compounds from a separate research collaboration and to expand its territory to include Greater China.
Deal terms and development role
Starna will receive an upfront payment of 330 million US dollars. The biotechnology company is also eligible for up to 2.3 billion US dollars in development and commercial milestone payments, plus royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and plans to manufacture finished drug product for initial clinical trials at its US facilities.
Pfizer will hold sole and exclusive commercialization control outside Greater China. The financial structure limits the immediate cash commitment to the upfront payment while leaving a larger portion of the potential consideration tied to development and commercial milestones. For investors, that places the near-term focus on clinical progress and the eventual ability of the programs to produce medicines rather than on immediate sales.
In vivo CAR-T therapies seek to reprogram immune cells directly inside the body so they can target disease-causing immune cells. That approach differs from conventional CAR-T treatment, which generally involves collecting and modifying a patient's cells outside the body before reinfusion. Starna's programs remain at an early stage, but the license gives Pfizer access to a platform that could broaden its pipeline beyond established therapies and vaccines.
Pipeline strategy meets patent pressure
The agreement adds another pipeline initiative as Pfizer works to offset upcoming patent losses and rebuild growth after the decline in COVID-related products. At a November 17 healthcare conference, Chief Executive Albert Bourla said Pfizer was targeting high single-digit growth from 2028 through 2033. He also highlighted a 32 percent increase in launch products and annualized revenue of 15 billion to 16 billion US dollars from those products.
Pfizer is combining licensing, acquisitions, new launches and cost reductions as it navigates the loss-of-exclusivity period. Bourla said the company had delivered 7.2 billion US dollars in net savings and had announced another 1.5 billion US dollars in reductions. The Starna deal therefore fits a broader effort to add future growth platforms while controlling development and operating costs.
Pfizer stock was last quoted at 25.75 euros on Lang & Schwarz at 2:41:21 p.m. CET on Wednesday, November 18, 0.43 percent below the Xetra close of Tuesday, November 17, at 25.86 euros. The quote reflects the market's position before the publication date and should be read alongside the clinical and regulatory risks attached to pre-IND programs.
Pfizer stock at a glance
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Trading venue: Lang & Schwarz
- Last quote: 25.75 euros on Wednesday, November 18, 2026, at 2:41:21 p.m. CET
- Xetra close: 25.86 euros on Tuesday, November 17, 2026
- Deal announced: Wednesday, November 18, 2026
US equities and pharmaceutical shares remain sensitive to pipeline milestones, patent timing and shifts in investor expectations for long-term growth. Broader market direction can be followed through the S&P 500.
For ongoing company developments, see More news and analyses on Pfizer stock.
